COVID-19

Hemostemix to Present Its Clinical Data of the Treatment of Severe Angina

Calgary, Alberta--(Newsfile Corp. - September 16, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), the leading autologous (patient's…

3 months ago

Christopher G Chute, MD, DrPH, FACMI, to Be Awarded Morris F. Collen Award of Excellence at the AMIA 2025 Annual Symposium

WASHINGTON, D.C. / ACCESS Newswire / September 16, 2025 / The American College of Medical Informatics (ACMI) will present the…

3 months ago

Jyong Biotech Announces Completion of Patient Enrollment of over 700 subjects in Phase II Clinical Trial of MCS‑8 for Prostate Cancer Prevention

New Taipei City, Taiwan, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (Nasdaq: MENS) (the “Company”, “Jyong Biotech”), a…

3 months ago

Jyong Biotech Announces Completion of Patient Enrollment of over 700 subjects in Phase II Clinical Trial of MCS‑8 for Prostate Cancer Prevention

New Taipei City, Taiwan, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (Nasdaq: MENS) (the “Company”, “Jyong Biotech”), a…

3 months ago

ORYZON Strengthens Patent Portfolio for Iadademstat and Vafidemstat with New Decisions to Grant

In Australia and EuropeMADRID and CAMBRIDGE, Mass., Sept. 16, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY),…

3 months ago

ORYZON Strengthens Patent Portfolio for Iadademstat and Vafidemstat with New Decisions to Grant

In Australia and EuropeMADRID and CAMBRIDGE, Mass., Sept. 16, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY),…

3 months ago

Moderna Announces Updated COVID-19 Vaccine Against LP.8.1 Variant Generates Strong Immune Response in Humans

Preliminary analysis showed the 2025-2026 formula of Spikevax generated greater than an 8-fold increase in LP.8.1-neutralizing antibodies across age groupsClinical…

3 months ago

RETRANSMISSION: NanoViricides to Present at the Life Science Executive Partnering (LSX) Congress in Boston on September 17, 2025

This release is being retransmitted for extra exposure to downstream sites. SHELTON, CT / ACCESS Newswire / September 11, 2025…

3 months ago

Hemostemix Announces TSXV Approval of Debt Settlement at $0.20 per Share

Calgary, Alberta--(Newsfile Corp. - September 10, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Company"), the leading autologous…

3 months ago

Gilead Sciences Commits to Veeva Vault CRM

Next generation CRM with deep capabilities and agentic AI PLEASANTON, Calif., Sept. 10, 2025 /PRNewswire/ -- Veeva Systems (NYSE: VEEV)…

3 months ago